The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients...
The EU has approved the use of Xarelto (rivaroxaban), from Bayer, to prevent cardiovascular events in patients with Acute Coronary...
The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bayer HealthCare's oral anticoagulant Xarelto (rivaroxaban)...
Acute coronary syndrome (ACS), consisting of acute myocardial infarction and unstable angina, is the most dangerous and fatal form of coronary heart disease. Acute coronary syndrome has sudden onset and rapid development, which may lead to malignant life-threatening conditions at any time.
Xarelto (rivaroxaban) from Bayer HealthCare, cuts the rate of heart attacks, strokes, myocardial infarction, and cardiovascular death compared to placebo,...
Aim: Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome. Our objective was to identify the possible molecular mechanisms of rivaroxaban that contributes to endothelial function
Background: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF) rely on retrospective, nonrandomized observational data.
Xarelto (rivaroxaban) from Bayer/Johnson & Johnson twice daily with standard anti- platelet therapy significantly reduced both the rate of cardiovascular...
The FDA Cardiovascular and Renal Drugs Advisory Committee has voted against the approval of the use of Xarelto (rivaroxaban), from...
The FDA has rejected for the second time, the supplemental new drug application for Xarelto (rivaroxaban) from Janssen Pharma/Bayer as...